Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Abstract: A longitudinal differential protection method for a transformer comprises: calculating a corrected parameter of a transformer according to a voltage and electrical parameters of the transformer, wherein the electrical parameters of the transformer comprise a rated capacity of the transformer, and the corrected parameter of the transformer comprise a capacity of the transformer.

Abstract: The present disclosure relates to a crystalline form of compound I and processes for preparation thereof. The present disclosure also relates to a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing serotonin, norepinephrine and dopamine triple reuptake inhibitors drugs, and/or use of the crystalline form for preparing drugs treating nervous system disorders. The crystalline form of the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development.

Abstract: The present disclosure relates to novel crystalline forms of compound I and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing crystalline forms, and use of crystalline forms for preparing drugs containing selective progesterone receptor modulator, and use of crystalline forms for preparing drugs treating uterine fibroids and/or endometriosis. The crystalline forms of the present disclosure have one or more improved properties compared with prior art and have significant values for future drug optimization and development.

Abstract: The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Abstract: A number of RSA computing tasks that have different word lengths which are less than a maximum word length of an operand register are processed at the same time by combining a number of different word lengths to be equal to or less than the maximum word length of the operand register.

Abstract: The present disclosure relates to novel crystalline forms of compound (I) and processes for preparation and use thereof. Crystalline forms CS3, CS2, CS5 and CS8 of compound (I) of the present disclosure have advantages in at least one aspect of solubility, stability, melting point, hygroscopicity, particle size, bioavailability, processability, purification effect, flowability, adhesiveness, stability in drug product, in vitro and in vivo dissolution, etc., which provides new and better choices for preparation of drug product containing compound (I) and has significant values for future drug development.

Abstract: The present disclosure relates to novel crystalline forms of Baricitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing these crystalline forms and use of these crystalline forms for preparing JAK inhibitor drugs and preparing drugs treating rheumatoid arthritis. The crystalline forms of the present disclosure have one or more improved properties compared with crystalline forms of the prior art, and have significant values for future drug optimization and development.

Abstract: The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.

Abstract: The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof.

Abstract: The present invention discloses a method for constructing linear luenberger observer for vehicle control. The method for constructing linear luenberger observer for vehicle control comprises the following steps: step 1: building a state-space equation of a driving system of a vehicle to judge observability of the driving system; step 2: dividing the state of the driving system into blocks, and reconstructing state components of the driving system to obtain an rewritten state observation equation of the driving system; step 3: introducing transformation into the rewritten state equation of the driving system to obtain an expression equation and an error equation of the Luenberger observer. The linear luenberger observer constructed by the present invention has low implementation difficulty. High-frequency noise in an output signal of a rotational speed sensor is reduced.

Abstract: The present disclosure relates to novel crystalline forms of VX-787, processes for preparation thereof and use thereof. VX-787 is a viral-protein inhibitor drug. The present disclosure provides crystalline form CS1, crystalline form CS2, crystalline form CS3, and crystalline form CS4 of compound (I) hydrochloride. The present disclosure also provides crystalline form CS3 and crystalline form CS9 of compound (I).free form.

Abstract: The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (I)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development.

Abstract: Disclosure is an aerosol generating article having a low temperature burning heat source, including a low temperature burning smoking set and a matching cigarette, the smoking set includes a heat insulation sleeve, an annular heat conductive barrel, a cover and a heat source cigarette lighter; the barrel is provided in an annular mounting groove at a left section of an inner wall of the sleeve, the cover is provided at a left end of the sleeve, a cavity of the barrel is filled with the heat source in a sealed manner; a plurality of electric heating columns are provided at a right end of the lighter; the cover is provided with a plurality of insertion holes, and after the plurality of electric heating columns are inserted into the plurality of insertion holes, the lighter gets in contact with the barrel to ignite the heat source in the barrel.

Abstract: A multi-frequency ultrasound therapy apparatus is configured to operate at its center frequency and at the higher harmonic of its center frequency. The center frequency can be for the entire apparatus or for each ultrasound source element. At least one source element can generate ultrasound energy at its center frequency while, simultaneously, at least another source element can generate ultrasound energy at the higher harmonic of its center frequency. In addition, the same source element can generate ultrasound energy at its center frequency and the higher harmonic of its center frequency, respectively, but at different times. A data storage unit that stores encrypted and encoded data is disposed on the apparatus. The encoded data includes a unique identification code of the apparatus, the condition of use of the apparatus, the center frequency of each source element, the ultrasound efficiency of each source element, and/or other parameters relating to the apparatus.

Abstract: A suppression method of high-frequency resonance for VSC-HVDC (Voltage Source Converter-High Voltage Direct Current Transmission) system based on nonlinear filter in voltage feed-forward control. It includes that the nonlinear filter is used for the voltage feed-forward link in the current inner loop control. The specific method is to extract each sequence component of the AC (Alternating Current) voltage, calculate the average value of the sequence component at N sample points, compare the current average value with the output result of nonlinear filter in the previous period, and output the result of nonlinear filter in the current period. After corrected, the result is a fixed value varying according to gradient which acts on the voltage feed-forward link of the inner loop.

Abstract: The present disclosure provides a novel crystalline form of Lemborexant and processes for preparation thereof. Pharmaceutical composition containing Lemborexant, and use of Lemborexant for preparing orexin receptor antagonist drug, and use of Lemborexant for preparing drugs treating insomnia and irregular sleep-wake rhythm disorder are also provided. The crystalline form of the present disclosure have one or more improved properties compared with crystalline forms of prior arts, and has significant values for future drug optimization and development.

Abstract: The present disclosure relates to novel crystalline forms of a bromodomain protein inhibitor 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquinazolin-4(3H)-one and processes for preparation and use thereof, relating to pharmaceutical industry. Form CS2, Form CS8, Form CS13, Form CS20, Form CS1, Form CS7, Form CS9, Form CS11 and Form CS4 of the present disclosure can be used for preparing drugs treating cardiovascular, cholesterol or lipid-related disorders.

Abstract: The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (I)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development.